shr-1701
Recombinant proteinexperimentalMulti-specific
Clinical trial activity
38 trials · 14 clinical orgs · 0 marketing orgs
Phase 1
13
Phase 2
29
Phase 3
5
Phase 4
0
Earliest trial started Nov 20, 2018 (NCT03710265)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Cholangiocarcinoma · Phase 2
- Colorectal Neoplasms · Phase 2/Phase 3
- Drugs, Investigational · Phase 2
- Esophageal Neoplasms · Phase 3
- Hodgkin Disease · Phase 1/Phase 2
- Lung Neoplasms · Phase 2
- Lymphoma · Phase 1/Phase 2
- Melanoma · Phase 2
- Nasopharyngeal Carcinoma · Phase 1/Phase 2
- Neoplasm Metastasis · Phase 1
- Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Neoplasms · Phase 2
- Uterine Cervical Neoplasms · Phase 3
Mechanism of action
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
- Transforming growth factor beta-1INHIBITOR
TGFB1 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07311408 | Phase 2 | Jan 1, 2026 | China Medical University |
| NCT07175220 | Phase 2 | Oct 9, 2025 | Hengrui Therapeutics, Inc. |
| NCT07102901 | Phase 2 | Sep 5, 2025 | Hengrui Therapeutics, Inc. |
| NCT07147088 | Phase 2 | Sep 1, 2025 | Fudan University |
| NCT07294664 | Phase 2 | Jun 15, 2025 | Zhengzhou University |
| NCT06893887 | N/A | May 22, 2025 | Nanjing Tianyinshan Hospital |
| NCT06881017 | Phase 2 | May 1, 2025 | China Medical University |
| NCT06679673 | Phase 2 | Dec 31, 2024 | Fudan University |
| NCT05896046 | Phase 1/Phase 2 (Phase 2) | Jun 14, 2023 | People's Liberation Army of China |
| NCT05671822 | Phase 2 | Mar 14, 2023 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT05503888 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2022 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT05300269 | Phase 2 | Jul 5, 2022 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT05179239 | Phase 3 | Feb 26, 2022 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT05198817 | Phase 1 | Feb 22, 2022 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT05177497 | Phase 2 | Jan 31, 2022 | Jiao Tong University |
| NCT05132413 | Phase 3 | Dec 30, 2021 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT05149807 | Phase 2/Phase 3 (Phase 3) | Dec 13, 2021 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT05106023 | Phase 2 | Oct 31, 2021 | Fudan University |
| NCT05048134 | Phase 1 | Oct 25, 2021 | Hengrui Therapeutics, Inc. |
| NCT05020925 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2021 | Hengrui Therapeutics, Inc. |
Showing 20 of 38 trials
Page 1 / 2
Organizations
Research & Development (14)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hengrui Therapeutics, Inc. | For profit | 13 | 13 | 2 | 2018 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | For profit | 11 | 11 | 3 | 2021 |
| Fudan University | Academic/Hospital | 4 | 4 | 1 | 2020 |
| China Medical University | Academic/Hospital | 2 | 2 | 1 | 2025 |
| People's Liberation Army of China | Government | 2 | 2 | 1 | 2020 |
| Atridia Pty Ltd. | For profit | 1 | 1 | 1 | 2020 |
| Central South University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Jiangsu Cancer Institute & Hospital | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Jiao Tong University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Nanjing Tianyinshan Hospital | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Shandong University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Shantou University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Zhengzhou University | Academic/Hospital | 1 | 1 | 1 | 2025 |
14 organizations
Page 1 / 1